Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study by Goss, Glenwood, Dr Prof, Tsai, Chun-Ming, Prof, Shepherd, Frances A, Prof, Bazhenova, Lyudmila, Prof, Lee, Jong Seok, MD, Chang, Gee-Chen, MD, Crino, Lucio, MD, Satouchi, Miyako, MD, Chu, Quincy, MD, Hida, Toyoaki, MD, Han, Ji-Youn, Prof, Juan, Oscar, MD, Dunphy, Frank, Prof, Nishio, Makoto, MD, Kang, Jin-Hyoung, MD, Majem, Margarita, MD, Mann, Helen, MSc, Cantarini, Mireille, MD, Ghiorghiu, Serban, MD, Mitsudomi, Tetsuya, Prof

Get full text

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study by Hellmann, Matthew D, Dr, Rizvi, Naiyer A, Prof, Goldman, Jonathan W, MD, Gettinger, Scott N, MD, Borghaei, Hossein, DO, Brahmer, Julie R, MD, Ready, Neal E, Prof, Gerber, David E, MD, Chow, Laura Q, MD, Juergens, Rosalyn A, MD, Shepherd, Frances A, Prof, Laurie, Scott A, MD, Geese, William J, PhD, Agrawal, Shruti, PhD, Young, Tina C, MS, Li, Xuemei, MD, Antonia, Scott J, Prof

Get full text

Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial by Albain, Kathy S, Prof, Swann, R Suzanne, PhD, Rusch, Valerie W, Prof, Turrisi, Andrew T, Prof, Shepherd, Frances A, Prof, Smith, Colum, Prof, Chen, Yuhchyau, Prof, Livingston, Robert B, Prof, Feins, Richard H, Prof, Gandara, David R, Prof, Fry, Willard A, Prof, Darling, Gail, Prof, Johnson, David H, Prof, Green, Mark R, Prof, Miller, Robert C, Prof, Ley, Joanne, RN, Sause, Willliam T, Prof, Cox, James D, Prof

Get full text

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial by Kim, Edward S, MD, Hirsh, Vera, MD, Mok, Tony, Prof, Socinski, Mark A, Prof, Gervais, Radj, MD, Wu, Yi-Long, Prof, Li, Long-Yun, Prof, Watkins, Claire L, MSc, Sellers, Mark V, MSc, Lowe, Elizabeth S, MD, Sun, Yan, MD, Liao, Mei-Lin, Prof, Østerlind, Kell, MD, Reck, Martin, MD, Armour, Alison A, FRCR, Shepherd, Frances A, Prof, Lippman, Scott M, Prof, Douillard, Jean-Yves, Prof

Get full text

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial by Butts, Charles, Dr, Socinski, Mark A, Prof, Mitchell, Paul L, MD, Thatcher, Nick, Prof, Havel, Libor, MD, Krzakowski, Maciej, Prof, Nawrocki, Sergiusz, MD, Ciuleanu, Tudor-Eliade, MD, Bosquée, Lionel, MD, Trigo, José Manuel, MD, Spira, Alexander, MD, Tremblay, Lise, MD, Nyman, Jan, MD, Ramlau, Rodryg, MD, Wickart-Johansson, Gun, MD, Ellis, Peter, MD, Gladkov, Oleg, MD, Pereira, José Rodrigues, MD, Eberhardt, Wilfried Ernst Erich, MD, Helwig, Christoph, Dipl Stat, Schröder, Andreas, MD, Shepherd, Frances A, Prof

Get full text

Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial by Ellis, Peter M, Dr, Shepherd, Frances A, Prof, Millward, Michael, Prof, Perrone, Francesco, PhD, Seymour, Lesley, Prof, Liu, Geoffrey, MD, Sun, Sophie, MD, Cho, Byoung Chul, MD, Morabito, Alessandro, MD, Leighl, Natasha B, MD, Stockler, Martin R, Prof, Lee, Christopher W, MD, Wierzbicki, Rafal, MD, Cohen, Victor, MD, Blais, Normand, MSc, Sangha, Randeep S, MD, Favaretto, Adolfo G, MD, Kang, Jin Hyoung, MD, Tsao, Ming-Sound, Prof, Wilson, Carolyn F, MSc, Goldberg, Zelanna, MD, Ding, Keyue, PhD, Goss, Glenwood D, Prof, Bradbury, Penelope Ann, MBBCh

Get full text

Molecular predictive and prognostic markers in non-small-cell lung cancer by Coate, Linda E, MD, John, Thomas, MD, Tsao, Ming-Sound, Prof, Shepherd, Frances A, Prof

Get full text

Non-small-cell lung cancer by Goldstraw, Peter, Prof, Ball, David, Prof, Jett, James R, MD, Le Chevalier, Thierry, MD, Lim, Eric, FRCS, Nicholson, Andrew G, Prof, Shepherd, Frances A, MD

Get full text

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data by Leo, Angelo Di, Dr, Desmedt, Christine, PhD, Bartlett, John M S, Prof, Piette, Fanny, PhD, Ejlertsen, Bent, MD, Pritchard, Kathleen I, Prof, Larsimont, Denis, MD, Poole, Christopher, Prof, Isola, Jorma, Prof, Earl, Helena, Prof, Mouridsen, Henning, MD, O'Malley, Frances P, MD, Cardoso, Fatima, MD, Tanner, Minna, MD, Munro, Alison, PhD, Twelves, Chris J, Prof, Sotiriou, Christos, MD, Shepherd, Lois, MD, Cameron, David, Prof, Piccart, Martine J, Prof, Buyse, Marc, PhD

Get full text

Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients... by Mauguen, Audrey, MSc, Pignon, Jean-Pierre, Dr, Burdett, Sarah, MSc, Domerg, Caroline, MSc, Fisher, David, MSc, Paulus, Rebecca, BS, Mandrekar, Samithra J, PhD, Belani, Chandra P, Prof, Shepherd, Frances A, MD, Eisen, Tim, Prof, Pang, Herbert, PhD, Collette, Laurence, PhD, Sause, William T, MD, Dahlberg, Suzanne E, PhD, Crawford, Jeffrey, Prof, O'Brien, Mary, MD, Schild, Steven E, MD, Parmar, Mahesh, DPhil, Tierney, Jayne F, PhD, Pechoux, Cécile Le, MD, Michiels, Stefan, PhD

Get full text

SARS-CoV-2 lineage dynamics in England from September to November 2021: high diversity of Delta sub-lineages and increased transmissibility of AY.4.2 by Eales, Oliver, Page, Andrew J, de Oliveira Martins, Leonardo, Wang, Haowei, Bodinier, Barbara, Haw, David, Jonnerby, Jakob, Atchison, Christina, Ashby, Deborah, Barclay, Wendy, Taylor, Graham, Cooke, Graham, Ward, Helen, Darzi, Ara, Riley, Steven, Chadeau-Hyam, Marc, Donnelly, Christl A, Elliott, Paul

Get full text